{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:41:16Z","timestamp":1782916876863,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00210-019-01653-y","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T23:03:18Z","timestamp":1556060598000},"page":"991-1004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?"],"prefix":"10.1007","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-3851","authenticated-orcid":false,"given":"Joachim","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"K\u00e4ufler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Gergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"issue":"7","key":"1653_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/bjp.2008.339","volume":"155","author":"F Afzal","year":"2008","unstructured":"Afzal F, Andressen KW, M\u00f8rk HK, Aronsen JM, Sjaastad I, Dahl CP, Skomedal T, Levy FO, Osnes JB, Qvigstad E (2008) 5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles. Br J Pharmacol 155(7):1005\u20131014. \n                    https:\/\/doi.org\/10.1038\/bjp.2008.339","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1653_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","volume":"188","author":"PJ Barnes","year":"2013","unstructured":"Barnes PJ (2013) Theophylline. Am J Respir Crit Care Med 188(8):901\u2013906. \n                    https:\/\/doi.org\/10.1164\/rccm.201302-0388PP","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1653_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58(3):488\u2013520. \n                    https:\/\/doi.org\/10.1124\/pr.58.3.5","journal-title":"Pharmacol Rev"},{"issue":"16","key":"1653_CR4","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/bph.13525","volume":"173","author":"E Berk","year":"2016","unstructured":"Berk E, Christ T, Schwarz S, Ravens U, Knaut M, Kaumann AJ (2016) In permanent atrial fibrillation, PDE3 reduces force responses to 5-HT, but PDE3 and PDE4 do not cause the blunting of atrial arrhythmias. Br J Pharmacol 173(16):2478\u20132489. \n                    https:\/\/doi.org\/10.1111\/bph.13525","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1653_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00005344-199109000-00012","volume":"18","author":"T Bethke","year":"1991","unstructured":"Bethke T, Klimkiewicz A, Kohl C, von der Leyen H, Mehl H, Mende U, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, D\u00f6ring V, Kalm\u00e1r P, Haverich A (1991) Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol 18(3):386\u2013397","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1653_CR6","first-page":"16","volume":"290","author":"YJ Chiu","year":"1999","unstructured":"Chiu YJ, Hu SH, Reid IA (1999) Inhibition of phosphodiesterase III with milrinone increases renin secretion in human subjects. J Pharmacol Exp Ther 290(1):16\u201319","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"1653_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1369\/jhc.5A6625.2005","volume":"53","author":"MR D\u2019Andrea","year":"2005","unstructured":"D\u2019Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S (2005) Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 53(7):895\u2013903","journal-title":"J Histochem Cytochem"},{"issue":"5","key":"1653_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0223-5234(00)00179-3","volume":"35","author":"V Dal Piaz","year":"2000","unstructured":"Dal Piaz V, Giovannoni MP (2000) Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem 35(5):463\u2013480","journal-title":"Eur J Med Chem"},{"issue":"3","key":"1653_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1124\/jpet.106.101329","volume":"317","author":"JH Maeyer De","year":"2006","unstructured":"De Maeyer JH, Prins NH, Schuurkes JA, Lefebvre RA (2006) Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J Pharmacol Exp Ther 317(3):955\u2013964. \n                    https:\/\/doi.org\/10.1124\/jpet.106.101329","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1653_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/sj.bjp.0707631","volume":"153","author":"A Galindo-Tovar","year":"2008","unstructured":"Galindo-Tovar A, Kaumann AJ (2008) Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (\u2212)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors. Br J Pharmacol 153(4):710\u2013720","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1653_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1476-5381.2008.00023.x","volume":"156","author":"A Galindo-Tovar","year":"2009","unstructured":"Galindo-Tovar A, Vargas ML, Escudero E, Kaumann AJ (2009) Ontogenic changes of the control by phosphodiesterase-3 and -4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT(4) receptors. Br J Pharmacol 156(2):237\u2013249. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2008.00023.x","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1653_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00210-015-1178-2","volume":"389","author":"A Galindo-Tovar","year":"2016","unstructured":"Galindo-Tovar A, Vargas ML, Kaumann AJ (2016) Inhibitors of phosphodiesterases PDE2, PDE3, and PDE4 do not increase the sinoatrial tachycardia of noradrenaline and prostaglandin PGE1 in mice. Naunyn Schmiedeberg\u2019s Arch Pharmacol 389(2):177\u2013186. \n                    https:\/\/doi.org\/10.1007\/s00210-015-1178-2","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1653_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00210-018-1480-x","volume":"391","author":"A Galindo-Tovar","year":"2018","unstructured":"Galindo-Tovar A, Vargas ML, Kaumann AJ (2018) Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce \u03b2-adrenoceptor-mediated chronotropic and inotropic effects in rat heart. Naunyn Schmiedeberg\u2019s Arch Pharmacol 391:571\u2013585. \n                    https:\/\/doi.org\/10.1007\/s00210-018-1480-x","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"4","key":"1653_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00210-008-0371-y","volume":"379","author":"U Gergs","year":"2009","unstructured":"Gergs U, Neumann J, Simm A, Silber RE, Remmers FO, L\u00e4er S (2009) Phosphorylation of phospholamban and troponin I through 5-HT4-receptors in the isolated human atrium. Naunyn Schmiedeberg\u2019s Arch Pharmacol 379(4):349\u2013359. \n                    https:\/\/doi.org\/10.1007\/s00210-008-0371-y","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"3","key":"1653_CR15","doi-asserted-by":"publisher","first-page":"H788","DOI":"10.1152\/ajpheart.00691.2009","volume":"299","author":"U Gergs","year":"2010","unstructured":"Gergs U, Baumann M, B\u00f6ckler A, Buchwalow IB, Ebelt H, Fabritz L, G\u00fcnther S, Hauptmann S, Kirchhof P, Kl\u00f6ckner U, P\u00f6nicke K, R\u00fcckschlo\u00df U, Schmitz W, Schulz N, Werner F, Neumann J (2010) Cardiac overexpression of the human 5-HT4-receptor in mice. Am J Physiol Heart Circ Physiol 299(3):H788\u2013H798. \n                    https:\/\/doi.org\/10.1152\/ajpheart.00691.2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"1653_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00210-013-0831-x","volume":"386","author":"U Gergs","year":"2013","unstructured":"Gergs U, B\u00f6ckler A, Ebelt H, Hauptmann S, Keller N, Otto V, P\u00f6nicke K, Schmitz W, Neumann J (2013) Human 5-HT4-receptor stimulation in atria of transgenic mice. Naunyn Schmiedeberg\u2019s Arch Pharmacol 386(5):357\u2013367. \n                    https:\/\/doi.org\/10.1007\/s00210-013-0831-x","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"6","key":"1653_CR17","doi-asserted-by":"publisher","first-page":"H1087","DOI":"10.1152\/ajpheart.00350.2017","volume":"313","author":"U Gergs","year":"2017","unstructured":"Gergs U, Jung F, Buchwalow IB, Hofmann B, Simm A, Treede H, Neumann J (2017) Pharmacological and physiological assessment of serotonin formation and degradation in isolated preparations from mouse and human heart. Am J Physiol Heart Circ Physiol 313(6):H1087\u2013H1097. \n                    https:\/\/doi.org\/10.1152\/ajpheart.00350.2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"1653_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1006\/bbrc.1998.9379","volume":"250","author":"M Hayashi","year":"1998","unstructured":"Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y, Tanaka T (1998) Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 250(3):751\u2013756","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1653_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/BF00169055","volume":"342","author":"AJ Kaumann","year":"1990","unstructured":"Kaumann AJ (1990) Piglet sinoatrial receptors resemble human atrial 5-HT4-like receptors. Naunyn Schmiedeberg\u2019s Arch Pharmacol 342(5):619\u2013622","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"7","key":"1653_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.tips.2011.03.003","volume":"32","author":"AJ Kaumann","year":"2011","unstructured":"Kaumann AJ (2011) Phosphodiesterases reduce spontaneous sinoatrial beating but not the \u2018fight or flight\u2019 tachycardia elicited by agonists through Gs-protein-coupled receptors. Trends Pharmacol Sci 32(7):377\u2013383. \n                    https:\/\/doi.org\/10.1016\/j.tips.2011.03.003","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"1653_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1476-5381.1990.tb14108.x","volume":"100","author":"AJ Kaumann","year":"1990","unstructured":"Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ (1990) A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol 100(4):879\u2013885. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.1990.tb14108.x","journal-title":"Br J Pharmacol"},{"key":"1653_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF00167212","volume":"344","author":"AJ Kaumann","year":"1991","unstructured":"Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ (1991) A 5-HT4-like receptor in human right atrium. Naunyn Schmiedeberg\u2019s Arch Pharmacol 344:150\u2013159","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1653_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/164_2016_82","volume":"243","author":"GE Kim","year":"2017","unstructured":"Kim GE, Kass DA (2017) Cardiac phosphodiesterases and their modulation for treating heart disease. Handb Exp Pharmacol 243:249\u2013269. \n                    https:\/\/doi.org\/10.1007\/164_2016_82","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"1653_CR24","doi-asserted-by":"publisher","first-page":"H2216","DOI":"10.1152\/ajpheart.00137.2004","volume":"287","author":"U Kirchhefer","year":"2004","unstructured":"Kirchhefer U, Baba HA, Hanske G, Jones LR, Kirchhof P, Schmitz W, Neumann J (2004) Age-dependent biochemical and contractile properties in atrium of transgenic mice overexpressing junctin. Am J Physiol Heart Circ Physiol 287(5):H2216\u2013H2225. \n                    https:\/\/doi.org\/10.1152\/ajpheart.00137.2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"1653_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1074248416679733","volume":"22","author":"RA Kloner","year":"2017","unstructured":"Kloner RA, Chaitman B (2017) Angina and its management. J Cardiovasc Pharmacol Ther 22(3):199\u2013209. \n                    https:\/\/doi.org\/10.1177\/1074248416679733 \n                    \n                   Epub 2016 Dec 14","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"1653_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290\u2013314. \n                    https:\/\/doi.org\/10.1038\/nrd4228","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1653_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sj.bjp.0705012","volume":"138","author":"J Neumann","year":"2003","unstructured":"Neumann J, Boknik P, Matherne GP, Lankford A, Schmitz W (2003) Pertussis toxin sensitive and insensitive effects of adenosine and carbachol in murine atria overexpressing A1\u2013adenosine receptors. Br J Pharmacol 138(1):209\u2013217. \n                    https:\/\/doi.org\/10.1038\/sj.bjp.070501","journal-title":"Br J Pharmacol"},{"issue":"23","key":"1653_CR28","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1111\/bph.12647","volume":"171","author":"O Orstavik","year":"2014","unstructured":"Orstavik O, Ata SH, Riise J, Dahl CP, Andersen G\u00d8, Levy FO, Skomedal T, Osnes JB, Qvigstad E (2014) Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol 171(23):5169\u20135181. \n                    https:\/\/doi.org\/10.1111\/bph.12647","journal-title":"Br J Pharmacol"},{"issue":"21","key":"1653_CR29","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"M Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325(21):1468\u20131475","journal-title":"N Engl J Med"},{"issue":"9485","key":"1653_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","volume":"366","author":"KF Rabe","year":"2005","unstructured":"Rabe KF, Bateman ED, O\u2019Donnell D, Witte S, Bredenbr\u00f6ker D, Bethke TD (2005) Roflumilast\u2014an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366(9485):563\u2013571. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)67100-0","journal-title":"Lancet"},{"issue":"2","key":"1653_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00395-010-0138-8","volume":"106","author":"W Richter","year":"2011","unstructured":"Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA, Conti M (2011) Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 106(2):249\u2013262. \n                    https:\/\/doi.org\/10.1007\/s00395-010-0138-8","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"1653_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/BF00176614","volume":"345","author":"L Sanders","year":"1992","unstructured":"Sanders L, Kaumann AJ (1992) A 5-HT4-like receptor in human left atrium. Naunyn Schmiedeberg\u2019s Arch Pharmacol 345(4):382\u2013386","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"9","key":"1653_CR33","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1161\/01.CIR.92.9.2526","volume":"92","author":"L Sanders","year":"1995","unstructured":"Sanders L, Lynham JA, Bond B, del Monte F, Harding S, Kaumann AJ (1995) Sensitization of human atrial 5-HT4 receptors by chronic \u03b2-blocker treatment. Circulation 92(9):2526\u20132539. \n                    https:\/\/doi.org\/10.1161\/01.CIR.92.9.2526","journal-title":"Circulation"},{"issue":"12","key":"1653_CR34","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","volume":"96","author":"SH Soderling","year":"1999","unstructured":"Soderling SH, Bayuga SJ, Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 96(12):7071\u20137076","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1653_CR35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.yjmcc.2009.06.014","volume":"47","author":"TM Vinogradova","year":"2009","unstructured":"Vinogradova TM, Lakatta EG (2009) Regulation of basal and reserve cardiac pacemaker function by interactions of cAMP-mediated PKA-dependent Ca2+ cycling with surface membrane channels. J Mol Cell Cardiol 47(4):456\u2013474. \n                    https:\/\/doi.org\/10.1016\/j.yjmcc.2009.06.014","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"1653_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1006\/bbrc.2000.3613","volume":"276","author":"P Wang","year":"2000","unstructured":"Wang P, Wu P, Egan RW, Billah MM (2000) Cloning, characterization, and tissue distribution of mouse phosphodiesterase 7A1. Biochem Biophys Res Commun 276(3):1271\u20131277","journal-title":"Biochem Biophys Res Commun"},{"key":"1653_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0378-1119(03)00733-9","volume":"314","author":"P Wang","year":"2003","unstructured":"Wang P, Wu P, Egan RW, Billah MM (2003) Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene. 314:15\u201327","journal-title":"Gene."},{"issue":"6","key":"1653_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00210-012-0746-y","volume":"385","author":"S Weninger","year":"2012","unstructured":"Weninger S, De Maeyer JH, Lefebvre RA (2012) Study of the regulation of the inotropic response to 5-HT4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium. Naunyn Schmiedeberg\u2019s Arch Pharmacol 385(6):565\u2013577. \n                    https:\/\/doi.org\/10.1007\/s00210-012-0746-y","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1653_CR39","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00210-013-0855-2","volume":"386","author":"S Weninger","year":"2013","unstructured":"Weninger S, De Maeyer JH, Lefebvre RA (2013) Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium. Naunyn Schmiedeberg\u2019s Arch Pharmacol 386:671\u2013684. \n                    https:\/\/doi.org\/10.1007\/s00210-013-0855-2","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"11","key":"1653_CR40","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.cellsig.2014.07.027","volume":"26","author":"S Weninger","year":"2014","unstructured":"Weninger S, Van Craenenbroeck K, Cameron RT, Vandeput F, Movsesian MA, Baillie GS, Lefebvre RA (2014) Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling. Cell Signal 26(11):2573\u20132582. \n                    https:\/\/doi.org\/10.1016\/j.cellsig.2014.07.027","journal-title":"Cell Signal"},{"issue":"6","key":"1653_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/BF01258467","volume":"349","author":"W Zimmermann","year":"1994","unstructured":"Zimmermann W, Scholz H, Schumacher C, Wenzlaff H, Haverich A (1994) Effects of saterinone and its enantiomers R(+)-saterinone and S(\u2212)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts. Naunyn Schmiedeberg\u2019s Arch Pharmacol 349(6):611\u2013618","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"9","key":"1653_CR42","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1074\/jbc.M510372200","volume":"281","author":"R Zoraghi","year":"2006","unstructured":"Zoraghi R, Corbin JD, Francis SH (2006) Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. J Biol Chem 281(9):5553\u20135558","journal-title":"J Biol Chem"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-019-01653-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T23:06:50Z","timestamp":1587596810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-019-01653-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1007\/s00210-019-01653-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"1 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}